1 / 4

Abciximab plus heparin versus bivalirudin : ISAR-REACT-4

Abciximab plus heparin versus bivalirudin : ISAR-REACT-4.

razi
Download Presentation

Abciximab plus heparin versus bivalirudin : ISAR-REACT-4

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Abciximab plus heparin versus bivalirudin: ISAR-REACT-4 Objective: to evaluate the efficacy of abciximab plus heparin versus bivalirudin in patients with non-ST-elevation MI undergoing PCIStudy: multicenterdouble-blindrandomizedcontrolled trialPopulation: patients withnon-ST segment elevation MI undergoing PCI Endpoint: composite death, re-MI, urgent TVR or major bleedingat 30 days

  2. Abciximab plus heparin versus bivalirudin: ISAR-REACT-4

  3. Abciximab plus heparin versus bivalirudin: ISAR-REACT-4

  4. Abciximab plus heparin versus bivalirudin: ISAR-REACT-4 Conclusion abciximab plus heparinwasassociatedwithsimilar major adverse events as bivalirudin. The major bleeding rate waslowerwithbivalirudin. Kastrati NEJM 2011;365:1980-9

More Related